Molecular Biology Reports

, Volume 46, Issue 2, pp 2039–2047 | Cite as

Anti-proliferative and anti-apoptotic potential effects of epigallocatechin-3-gallate and/or metformin on hepatocellular carcinoma cells: in vitro study

  • Dina Sabry
  • Omayma O. AbdelaleemEmail author
  • Amani M. El Amin Ali
  • Rehab A. Mohammed
  • Nehal D. Abdel-Hameed
  • Amira Hassouna
  • Warda A. Khalifa
Original Article


The effects of epigallocatechin-3-gallate (EGCG) and metformin single treatment have been tested against hepatocellular carcinoma (HCC). This study aimed to assess the combination effects of EGCG and metformin on proliferation and apoptosis of HepG2cells and identified new potential molecular targets. The effect of EGCG and metformin against cell proliferation in HepG2 was determined using MTT assay. Reverse transcription polymerase chain reaction was applied to examine the gene expression of cyclin D1, lncRNA-AF085935, caspase-3, survivin and VEGF. The level of protein expression of glypican-3 was assessed by western blot. In HepG2 cells, EGCG and metformin combination treatment exhibited high significant effect against tumor proliferation. It significantly reduced cyclin D1, lncRNA-AF085935, glypican-3 and promoted apoptosis through increasing caspase3 and decreasing survivin compared to control cells. Moreover, EGCG and metformin treated cells showed decreased expression levels of VEGF. Our study provided new insights of the anticarcinogenic effects of EGCG and metformin on HCC through their effects on glypican-3 and lncRNA-AF085935.


Hepatocellular carcinoma EGCG Metformin Glypican-3 LncRNA-AF085935 


Compliance with Ethical Standards

Conflict of interest

All authors declared that there was no conflict of interest.


  1. 1.
    Bosch FX, Ribes J, Diaz M, Cleries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127:S5–S16CrossRefPubMedGoogle Scholar
  2. 2.
    Hengartner MO, Horvitz HR (1994) Programmed cell death in Caenorhabditis elegans. Curr Opin Genet Dev 4:581–586CrossRefPubMedGoogle Scholar
  3. 3.
    Holcik M, Korneluk RG (2001) XIAP, the guardian angel. Nat Rev Mol Cell Biol 2:550–556CrossRefPubMedGoogle Scholar
  4. 4.
    Goyal L (2001) Cell death inhibition: keeping caspases in check. Cell 104:805–808CrossRefPubMedGoogle Scholar
  5. 5.
    Jung YD, Kim MS, Shin BA (2001) EGCG, a major component of green tea, inhibit tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer 84:844–850CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sartippour MR, Heber D, Ma J, Lu Q, Go VL, Nguyen M (2001) Green tea and its catechins inhibit breast cancer xenografts. Nutr Cancer 40:149–156CrossRefPubMedGoogle Scholar
  7. 7.
    Zhou DH, Wang X, Feng Q (2014) EGCG enhances the efficacy of cisplatin by downregulating hsa-miR-98-5p in NSCLC A549 cells. Nutr Cancer 66:636–644. CrossRefPubMedGoogle Scholar
  8. 8.
    Ma SJ, Zheng YX, Zhou PC, Xiao YN, Tan HZ (2016) Metformin use improves survival of diabetic liver cancer patients: systematic review and meta analysis. Oncotarget 7(40):66202–66211PubMedPubMedCentralGoogle Scholar
  9. 9.
    Albini A, Tosetti F, Li VW, Noonan DM, Li WW (2012) Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol 9:498–509CrossRefPubMedGoogle Scholar
  10. 10.
    Filmus J, Selleck SB (2001) Glypicans: proteoglycans with a surprise. J Clin Invest 108:497–501CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wang XY, Degos F, Dubois S, Tessiore S, Allegretta M, Guttmann RD, Jothy S, Belghiti J, Bedossa P, Paradis V (2006) Glypican 3 expression in hepatocellular tumors: diagnostic value for pre neoplastic lesions and hepatocellular carcinomas. Hum Pathol 37:1435–1441CrossRefPubMedGoogle Scholar
  12. 12.
    Filmus J, Capurro M (2013) Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J 280:2471–2476CrossRefPubMedGoogle Scholar
  13. 13.
    Zhao Y, Guo Q, Chen J, Hu J, Wang S, Sun Y (2014) Role of long noncoding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. Oncol Rep 31:358–364CrossRefPubMedGoogle Scholar
  14. 14.
    Zhang W, Huang C, Gong Z, Zhao Y, Tang K, Li X (2013) Expression of LINC00312, a long intergenic non-coding RNA, is negatively correlated with tumor size but positively correlated with lymph node metastasis in nasopharyngeal carcinoma. J Mol Histol 44:545–554CrossRefPubMedGoogle Scholar
  15. 15.
    Weber DG, Johnen G, Casjens S, Bryk O, Pesch B, Jockel KH (2013) Evaluation of long noncoding RNA MALAT1 as a candidate blood based biomarker for the diagnosis of non-small cell lung cancer. BMC Res 6:518. CrossRefGoogle Scholar
  16. 16.
    Lu J, Xie F, Geng L, Shen W, Sui C, Yang J (2015) Investigation of serum lncRNA-uc003wbd and lncRNA-AF085935 expression profile in patients with hepatocellular carcinoma and HBV. Tumour Biol 36:3231–3236CrossRefPubMedGoogle Scholar
  17. 17.
    Osaki Y, Nishikawa H (2015) Treatment for hepatocellular carcinoma in Japan over the last three decades: our experience and published work review. Hepatol Res 45:59–74CrossRefPubMedGoogle Scholar
  18. 18.
    Li S, Wu L, Jiao F, Li J, Liu T, Rong Z, Shizan X, Keran C, Yuqing Z, Shunfeng Z, Rui K, Kan C, Fan W, Yujing X, Lu J, Yingqun Z, Weiqi D, Chuanyong G (2016) In vitro and in vivo study of epigallocatechin-3-gallate-induced apoptosis in aerobic glycolytic hepatocellular carcinoma cells involving inhibition of phosphofructokinase activity. Sci Rep 6:28479CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kuo PL, Lin CC (2003) Green tea constituent (–)-epigallocatechin-3- gallate inhibits Hep G2 cell proliferation and induces apoptosis through p53-dependent and Fas-mediated pathways. J Biomed Sci 10:219–227PubMedGoogle Scholar
  20. 20.
    Zhuang Y, Miskimins WK (2011) Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase dependent cell death in breast cancer cells. Mol Cancer Res 9:603–615CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Biliran HJ, Wang Y, Banerjee S (2005) Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene expressing pancreatic tumor cell line. Clin Cancer Res 11:6075–6086CrossRefPubMedGoogle Scholar
  22. 22.
    Zhuang Y, Miskimins WK (2008) Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 3:18CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Zhang X, Min KW, Wimalasena J, Baek SJ (2012) Cyclin D1 degradation and p21 induction contribute to growth inhibition of colorectal cancer cells induced by epigallocatechin-3-gallate. J Cancer Res Clin Oncol 138:2051–2060CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Sur S, Pal D, Mandal S, Roy A, Panda CK (2016) Tea polyphenols epigallocatechin gallete and theaflavin restrict mouse liver carcinogenesis through modulation of self-renewal Wnt and hedgehog pathways. J Nutr Biochem 27:32–42CrossRefPubMedGoogle Scholar
  25. 25.
    Cai X, Hu X, Cai B, Wang Q, Li Y, Tan X, Hu H, Chen X, Huang J, Cheng J, Jing X (2013) Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo. Oncol Rep 30:2449–2457CrossRefPubMedGoogle Scholar
  26. 26.
    DePeralta DK, Wei L, Lauwers GY, Fuchs BC, Tanabe KK (2014) Metformin inhibits hepatocellular carcinoma in a cirrhosis model. J Surg Res 186:633CrossRefGoogle Scholar
  27. 27.
    Yuan SX, Tao QF, Wang J, Yang F, Liu L, Wang LL, Zhang J, Yang Y, Liu H, Wang F (2014) Antisense long non-coding RNA PCNA-AS1 promotes tumour growth by regulating proliferating cell nuclear antigen in hepatocellular carcinoma. Cancer Lett 349:87–94CrossRefPubMedGoogle Scholar
  28. 28.
    Lu H, He Y, Lin L, Qi Z, Ma L, Li L, Su Y (2016) Long non-coding RNA MALAT1 modulates radiosensitivity of HR-HPV + cervical cancer via sponging miR-145. Tumour Biol 37:1683–1691CrossRefPubMedGoogle Scholar
  29. 29.
    Xiao-ting Z, Ji-hang Y, Teng-teng Z, Yang-yang L and Xiao-yang C. (2016) Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3. FEBS J. 283:3739–3754Google Scholar
  30. 30.
    Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J (2003) Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125:81–90CrossRefGoogle Scholar
  31. 31.
    Shirakawa H (2009) Glypican-3 expression is correlated with poor prognosis hepatocellular carcinoma. Cancer Sci 100:1403–1407CrossRefPubMedGoogle Scholar
  32. 32.
    Zittermann SI, Capurro MI, Shi W, Filmus J (2010) Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer 126:1291–1301PubMedGoogle Scholar
  33. 33.
    Feng M, Kim H, Phung Y, Ho M (2011) Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro. Int J Cancer 128:2246–2247CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Salvesen GS (2002) Caspases and apoptosis. Essays Biochem 38:9–19CrossRefPubMedGoogle Scholar
  35. 35.
    Gonzalez F (2014) Green tea extract induces apoptosis in the AGS gastric carcinoma cell line. Nat Prod Chem Res 2:130CrossRefGoogle Scholar
  36. 36.
    Nishikawa T, Nakajima T, Moriguchi M (2006) A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of bcl-2 family proteins. J Hepatol 44:1074–1082CrossRefPubMedGoogle Scholar
  37. 37.
    Zhan Q, Yangde Z, Mingmei L, Yuxiang C, Jinfeng Z, Yifeng P (2012) In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma. Hepatol Res 42:922–933CrossRefGoogle Scholar
  38. 38.
    Xiong Y, Lu QJ, Zhao J, Wu GY (2012) Metformin inhibits growth of hepatocellular carcinoma cells by inducing apoptosis via mitochondrion-mediated pathway. Asian Pacif J Cancer Prev 13(7):3275–3279CrossRefGoogle Scholar
  39. 39.
    Kanwar RK, Cheung CH, Chang JY, Kanwar JR (2010) Recent advances in antisurvivin treatments for cancer. Curr Med Chem 17:1509–1515CrossRefPubMedGoogle Scholar
  40. 40.
    Su C (2016) Survivin in survival of hepatocellular carcinoma. Cancer Lett 2:184–190CrossRefGoogle Scholar
  41. 41.
    Chen X, Li Y, Lin Q, Wang Y, Sun H, Wang J, Cui G, Cai L, Dong X (2014) Tea polyphenols induced apoptosis of breast cancer cells by suppressing the expression of Survivin. Sci Rep 4:4416CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Mise M, Arii S, Higashituji H (1996) Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 23:455–464CrossRefPubMedGoogle Scholar
  43. 43.
    Torimura T, Sata M, Ueno T (1998) Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 29:986–991CrossRefPubMedGoogle Scholar
  44. 44.
    Masuda M, Suzui M, Lim JT, Deguchi A, Soh JW, Weinstein IB (2002) Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol 2:350–359CrossRefPubMedGoogle Scholar
  45. 45.
    Jung YD, Kim MS, Shin BA (2001) EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer 84:844–850CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Zhang Q, Tang X, Lu Q, Zhang Z, Rao J, Le AD (2006) Green tea extract and (–) epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol Cancer Ther 5:1227–1238CrossRefPubMedGoogle Scholar
  47. 47.
    Shirakami Y, Shimizu M, Adachi S (2009) (–)-Epigallocate-chin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. Cancer Sci 100:1957–1962. [PubMed: 19558547]CrossRefPubMedGoogle Scholar
  48. 48.
    Qingyun Z, Jian K, Shuying D, Wenlei Xu, Wenbing SZ (2017) Metformin exhibits the antiproliferation and antiinvasion effects in hepatocellular carcinoma cells after insufficient radiofrequency ablation. Cancer Cell Int 17:48CrossRefGoogle Scholar
  49. 49.
    Qu H, Yang X (2015) Metformin inhibits angiogenesis induced by interaction of hepatocellular carcinoma with hepatic stellate cells. Cell Biochem Biophys 2:931–936CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Medical Biochemistry and Molecular Biology, Faculty of MedicineCairo UniversityCairoEgypt
  2. 2.Medical Biochemistry and Molecular Biology Department, Faculty of MedicineFayoum UniversityFayoumEgypt
  3. 3.Medical Physiology Department, Faculty of MedicineFayoum UniversityFayoumEgypt
  4. 4.Clinical Pathology Departments, Faculty of MedicineCairo UniversityCairoEgypt
  5. 5.School of Interprofessional Health Studies, Faculty of Health and Environmental SciencesAuckland University of Technology (AUT)AucklandNew Zealand
  6. 6.Biotechnology Department, Faculty of ScienceSebha UniversitySabhaLibya

Personalised recommendations